Vietnam Japan Medical Investment and Development Joint Stock Company (JVC) successfully held its Extraordinary General Meeting of Shareholders (EGM) 2025 on the afternoon of November 3, 2025, at the 8th-floor auditorium, VNCC Building, No. 243 De La Thanh, Lang Ward, Hanoi.

The meeting was chaired by the Presidium, including:

• Mr. Vu Khanh Din – Chairman of the Board of Directors – Chairman of the Meeting
• Mr. Pham Thanh Nam – Vice Chairman of the Board of Directors – Member of the Presidium
• Mr. Vu Van Toan – General Director – Member of the Presidium

The Presidium conducted the meeting openly and transparently, ensuring shareholders’ rights to speak, discuss, and vote.

During the meeting, the Presidium presented five important proposals for shareholder consideration:

• Proposal for approval of the Company’s name change
• Proposal for amendment and supplementation of the Company’s business lines
• Proposal for amendment and supplementation of several provisions in the Company’s Charter and continuation of the private placement plan
• Proposal for increasing the number of and electing additional independent Board members for the 2021–2026 term
• Announcement of candidates for the additional election of independent Board members for the remainder of the 2021–2026 term

All proposals presented at the meeting were discussed openly and seriously by shareholders. Each proposal received strong consensus and was approved in accordance with regulations.

During the discussion session, many shareholders expressed their interest in the Company’s strategic business direction for the coming period, particularly regarding its expansion into the pharmaceutical industry. Responding to shareholder inquiries on this topic, Vu Van Toan – General Director – shared:

“Regarding the orientation toward the pharmaceutical sector: the medical equipment market, especially diagnostic imaging, is gradually becoming saturated with intense price competition, requiring expansion into areas with more attractive profit margins and long-term growth potential. The Company has chosen the pharmaceutical sector because demand for medicines in Vietnam is both large and essential, with substantial market gaps, high growth potential, and government incentives to promote domestic production and reduce dependence on imports.

In addition, the Company has experience, strong relationships with hospitals and clinics, and a nationwide medical partner network, providing an advantage when expanding into pharmaceuticals. This expansion helps mitigate risks inherent in relying on a single business sector. The shift does not mean abandonment, but rather aims to broaden the Company’s healthcare ecosystem; the combination of medical equipment and pharmaceuticals is intended to provide comprehensive healthcare solutions for the public.”

This message reflects the Company’s clear strategy to build an integrated healthcare ecosystem, leveraging its strengths in medical equipment while expanding into the pharmaceutical field-an area projected to experience robust growth and play a key role in Vietnam’s national healthcare strategy in the coming years.

The Extraordinary General Meeting of Shareholders 2025 marks a significant milestone for JVC as it proactively restructures, expands business areas, strengthens governance capacity, and targets high-potential sectors. The resolutions adopted at the meeting form an important foundation for realizing the Company’s long-term growth goals and building a comprehensive healthcare ecosystem.

The successful organization of the 2025 EGM demonstrates strong alignment between the Management Board and shareholders, affirming confidence in the Company’s new strategic direction.

JVC sincerely thanks its valued shareholders, partners, and customers for their trust and continued support. The Company remains committed to innovation and operational excellence, providing advanced, comprehensive, and high-quality healthcare solutions, while contributing to the development of Vietnam’s healthcare sector.